American Century Companies Inc. Has $3.13 Million Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

American Century Companies Inc. boosted its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 55.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 112,442 shares of the company's stock after purchasing an additional 39,932 shares during the quarter. American Century Companies Inc. owned 0.16% of Akero Therapeutics worth $3,128,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. AlphaQuest LLC grew its holdings in shares of Akero Therapeutics by 32,588.0% in the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after buying an additional 8,147 shares during the period. XTX Topco Ltd acquired a new position in Akero Therapeutics in the third quarter valued at about $308,000. Proficio Capital Partners LLC bought a new stake in shares of Akero Therapeutics in the fourth quarter worth about $320,000. Teacher Retirement System of Texas raised its position in shares of Akero Therapeutics by 18.7% during the fourth quarter. Teacher Retirement System of Texas now owns 14,415 shares of the company's stock worth $401,000 after purchasing an additional 2,274 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Akero Therapeutics by 10.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company's stock valued at $412,000 after purchasing an additional 1,446 shares in the last quarter.

Insiders Place Their Bets

In other Akero Therapeutics news, CFO William Richard White sold 676 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total transaction of $30,338.88. Following the completion of the transaction, the chief financial officer now owns 61,959 shares of the company's stock, valued at approximately $2,780,719.92. The trade was a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Cheng sold 30,000 shares of the stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $35.23, for a total transaction of $1,056,900.00. Following the completion of the transaction, the chief executive officer now directly owns 624,324 shares of the company's stock, valued at $21,994,934.52. This trade represents a 4.58 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders acquired 341,309 shares of company stock worth $15,863,578 and sold 278,385 shares worth $13,345,929. Corporate insiders own 7.94% of the company's stock.

Remove Ads

Akero Therapeutics Price Performance

NASDAQ AKRO traded up $0.85 during midday trading on Friday, hitting $35.67. The company had a trading volume of 814,604 shares, compared to its average volume of 857,773. The company has a market capitalization of $2.84 billion, a PE ratio of -9.51 and a beta of -0.18. Akero Therapeutics, Inc. has a twelve month low of $17.86 and a twelve month high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $44.86 and a 200-day moving average price of $35.86.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.01). As a group, analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on AKRO. UBS Group raised their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Citigroup raised their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Bank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. HC Wainwright upped their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Monday, March 3rd. Finally, Canaccord Genuity Group raised their price target on Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.